1. The costs of treatment of early and chronic Pseudomonas aeruginosa infection in cystic fibrosis patients.
- Author
-
Braccini G, Festini F, Boni V, Neri AS, Galici V, Campana S, Zavataro L, Trevisan F, Braggion C, and Taccetti G
- Subjects
- Adult, Anti-Bacterial Agents therapeutic use, Ceftazidime economics, Ceftazidime therapeutic use, Child, Preschool, Chronic Disease, Ciprofloxacin economics, Ciprofloxacin therapeutic use, Clavulanic Acids economics, Clavulanic Acids therapeutic use, Colistin economics, Colistin therapeutic use, Cystic Fibrosis complications, Humans, Meropenem, Pseudomonas Infections etiology, Pseudomonas aeruginosa, Retrospective Studies, Thienamycins economics, Thienamycins therapeutic use, Ticarcillin economics, Ticarcillin therapeutic use, Tobramycin economics, Tobramycin therapeutic use, Anti-Bacterial Agents economics, Cost of Illness, Cystic Fibrosis drug therapy, Cystic Fibrosis economics, Pseudomonas Infections drug therapy, Pseudomonas Infections economics
- Abstract
The aim of cystic fibrosis (CF) care is to improve both the life expectancy and quality of life of patients. However, rising costs and limited resources of health services must be taken into account. There are many different antibiotic strategies for therapy of Pseudomonas aeruginosa infection in CF patients. In this 5-year retrospective study we found that the cost of treatment of initial infection is considerably lower than the cost of treating chronic P. aeruginosa infections. The percentage distribution of costs of antibiotic treatment in relationship to the administration route was considerably different between outpatients and inpatients. We observed an increase in antibiotic costs with the age of the patient and the decrease in FEV(1)values. The implementation of early eradication treatment, in addition to decreasing the prevalence of patients chronically infected by P. aeruginosa, might also bring about a notable decrease in costs.
- Published
- 2009
- Full Text
- View/download PDF